Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/01443615.2020.1716315 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Keep on Keeping on - Mirena IUD for 8 Years.
J Am Board Fam Med
January 2025
From the University of Missouri, Columbia, MO (SHM, CT, LM).
Counsel patients that their Mirena IUD retains contraceptive effectiveness for extended use up to 8 years. The cumulative failure rate for years 6 through 8 was 0.68%, similar to reported rates for the first 5 years of use.
View Article and Find Full Text PDFFertility Sparing in Endometrial Cancer: Where Are We Now?
Cancers (Basel)
January 2025
Department of Molecular and Developmental Medicine, Obstetrics and Gynecological Clinic, University of Siena, 53100 Siena, Italy.
Endometrial cancer is the most common gynecological neoplasm with an increased incidence in the premenopausal population in recent decades. This raises the problem of managing endometrial cancer in fertile women who have not yet achieved pregnancy. In these women, after careful selection, hysterectomy may be postponed in favor of conservative management if specific requirements are met.
View Article and Find Full Text PDFState of the art endocrine treatments for patients diagnosed with endometrial cancer in 2025.
Curr Opin Obstet Gynecol
December 2024
Mount Sinai Medical Center, Miami Beach, Florida, USA.
Purpose Of Review: Endometrial cancer (EC) is rising in incidence, particularly in younger, premenopausal women, due to increasing rates of obesity and delayed childbearing. This review evaluates current and emerging endocrine therapies, with a focus on fertility-preserving approaches for early-stage EC and treatment options for advanced or recurrent disease.
Recent Findings: Fertility-sparing endocrine therapies, such as medroxyprogesterone acetate, megestrol acetate, and levonorgestrel-releasing intrauterine devices, achieve high response rates but carry recurrence risks.
Pain scores at the insertion of the levonorgestrel-releasing intrauterine system among paralympic athletes: Findings from Kyleena® Paralympic sport performance study.
Eur J Obstet Gynecol Reprod Biol
December 2024
Universidade Estadual de Campinas (UNICAMP), Brazil.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!